{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:52:31Z","timestamp":1778640751799,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> Macroprolactin, which comprises immunoglobulin G (IgG) or anti\u2010prolactin (PRL) autoantibody\u2010bound PRL, is one of the causes of hyperprolactinaemia. This study evaluated the composition and stability of macroprolactin and determined whether the condition was long lasting. We also investigated whether we could predict the composition of macroprolactin based on the ratio of polyethylene glycol (PEG)\u2010precipitable PRL.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> Two hundred and ninety\u2010two patients with hyperprolactinaemia (252 women and 40 men).<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> We used PEG precipitation to screen for macroprolactinaemia in 625 serum samples from 292 patients with hyperprolactinaemia visiting a city hospital over the last 5\u00b75\u2003years. Macroprolactinaemia was defined by PEG\u2010precipitable PRL ratio greater than 60%. IgG\u2010bound PRL and anti\u2010PRL autoantibodies were measured by protein G and <jats:sup>125<\/jats:sup>I\u2010hPRL binding studies, respectively. We also examined the autoantibody specificity and binding characteristics.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In 39 patients with macroprolactinaemia, IgG\u2010bound PRL was present in 87% and anti\u2010PRL autoantibodies in 67%. A non\u2010IgG\u2010bound form of macroprolactin was found mainly in sera with marginally elevated PEG\u2010precipitable PRL. The higher the PEG\u2010precipitable PRL ratio, the greater the likelihood that autoantibodies were involved in the composition of macroprolactin. The autoantibodies were IgG type and specific to human PRL and had a low affinity and high capacity. Long\u2010term follow\u2010up (2\u201317\u2003years) revealed that the ratios of PEG\u2010precipitable PRL, IgG\u2010bound PRL and anti\u2010PRL autoantibody\u2010bound PRL were relatively stable.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This study showed that higher PEG\u2010precipitable PRL ratio in macroprolactinaemic sera might preferentially indicate the presence of anti\u2010PRL autoantibodies and that macroprolactinaemia might be a long\u2010lasting condition.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2010.03880.x","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T18:27:18Z","timestamp":1285612038000},"page":"792-797","source":"Crossref","is-referenced-by-count":22,"title":["Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long\u2010term follow\u2010up"],"prefix":"10.1111","volume":"73","author":[{"given":"Naoki","family":"Hattori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365519509089606"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/000456329703400305"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00757.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8272"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02243.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2234"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.6.7521"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03570.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1831"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02548.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02980.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03001.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1211358"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1373\/49.3.502"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490201"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345304"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.5.1226"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.06871"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03402.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.2.586"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/clinchem\/44.8.1758","article-title":"Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinaemia","volume":"44","author":"Vieira J.G.","year":"1998","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_23_2","first-page":"436","article-title":"Polyethylene glycol precipitation as a screening method for macroprolactinaemia","volume":"45","author":"Fahie\u2010Wilson M.N.","year":"1999","journal-title":"Clinical Chemistry"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1373\/49.9.1504"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.9.3107"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.40.9.1187"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.12.4217"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0114"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2010.03880.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2010.03880.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:38:12Z","timestamp":1698784692000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2010.03880.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1365-2265.2010.03880.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03880.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}